GlassScriptPhysician profile
Kevin M French
NPI 1639140775
$2,740.40
in general payments reported to CMS, 2019-2025
35 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $271 · 2021: $511 · 2022: $218 · 2023: $409 · 2024: $444 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $443.71 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $302.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $296.89 | 2021-2024 | |
| Glaxosmithkline, LLC. | $214.06 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $180.88 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Lilly USA, LLC | $171.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $143.23 | 2019-2025 | |
| Astellas Pharma US INC | $137.90 | 2020-2025 | Veozah |
| Amarin Pharma, INC. | $100.72 | 2019-2021 | |
| Daiichi Sankyo INC. | $73.43 | 2020-2022 | |
| Allergan, INC. | $67.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $59.13 | 2019-2024 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.40 | 2019-2025 | Xifaxan |
| Dexcom, INC. | $51.00 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $40.72 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $37.01 | 2022-2024 | Inceptiv |
| Baxter Healthcare | $29.27 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Vertex Pharmaceuticals Incorporated | $28.84 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.72 | 2021-2024 | |
| C2n Diagnostics, LLC | $24.76 | 2025 | Precivityad2 |
| Actelion Pharmaceuticals US, INC. | $22.63 | 2025 | Opsumit, Uptravi |
| Sumitomo Pharma America, INC. | $21.99 | 2024 | Gemtesa |
| Genentech USA, INC. | $21.12 | 2020 | |
| Optinose US, INC. | $19.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.37 | 2023 | Xarelto |
| Grifols USA, LLC | $18.92 | 2019 | |
| Supernus Pharmaceuticals, INC. | $18.87 | 2019 | |
| Advanced Respiratory, INC | $18.61 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.20 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $14.79 | 2023 | Nexletol |
| Arbor Pharmaceuticals, INC. | $14.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.08 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.95 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.43 | 2022 | |
| Csl Behring | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin French listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.